| [1] |
Hudolin T,Kastelan Z,Derezi? D,et al.Expression of MAGEA1, MAGE-A3/4 and NY-ESO-1 cancer-testis antigens in fetal testis[J].Acta Dermatovenerol Croat, 2009,17(2):103-7.
|
| [2] |
Chen JL,Stewart-Jones G,Bossi G,et al.Structural and kinetic basis for heightened immunogenicity of T cell vaccines[J].J Exp Med,2005,201(8):1243-55.
|
| [3] |
Zhao Y,Zheng Z,Khong HT,et al.Transduction of an HLA-DP4- restricted NY-ESO-1 specificTCR into primary human CD4+ lymphocytes[J].J Immunother, 2006,29(4):398-406.
|
| [4] |
Purbhoo MA,Sutton DH,Brewer JE,et al.Quantifying and imaging NYESO- 1/ LAGE-1-derived epitopes on tumor cells using high affi nity T cell receptors[J].J Immunol,2006,176(12):7308-16.
|
| [5] |
Chapman C,Murray A,Chakrabarti J,et al.Autoantibodies in breast cancer: their use as an aid to early diagnosis[J].Ann Oncol,2007,18(5):868-73.
|
| [6] |
Milne K,Barnes RO,Girardin A,et al.Tumor-infi ltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer[J].PLoS One,2008,3(10): e3409.
|
| [7] |
Isobe M,Eikawa S,Uenaka A,et al.Correlationof high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient[J].Cancer Immun,2009,9:8.
|
| [8] |
Sang M, Lian Y, Zhou X, et al. MAGE-A family: attractive targets for cancer immunotherapy[J]. Vaccine. 2011, 29(47):8496-500.
|
| [9] |
Kavalar R,Sarcevic B,Spagnoli GC,et al.Expression of MAGE tumourassociated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study[J]. Virchows Arch,2001, 439(2):127-31.
|
| [10] |
Liang S,Xu DG,Zhang ZY,et al.Expression and Significance of antigens NY-ESO-1 and MAGE-A1 in breast carcinoma tissue[J]. Zhong Liu Fang Zhi Yan Jiu,2012,39(6):698-700.[梁爽，徐殿国，张 振翼，等. NY-ESO-1与MAGE-A1在乳腺癌组织中的表达及意义 [J] 肿瘤防治研究, 2012, 39(6): 698-700.]
|
| [11] |
Matkovi? B, Jureti? A, Spagnoli GC, et al. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study[J].Croat Med J,2011,52(2):171-7.
|
| [12] |
Adams S,Greeder L,Reich E,et al.Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?[J]. Cancer Immunol Immunother, 2011, 60(7): 99 9-1007.
|
| [13] |
Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? [J]. Diagn Mol Pathol, 2009, 18(3):125-32.
|
| [14] |
Ademuyiwa FO, Bshara W, Attwood K, et al. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer[J]. PLoS One, 2012, 7(6):e38783.
|
| [15] |
Badovinac ?rnjevi? T, Spagnoli G, Jureti? A,et al. High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer[J]. Med Oncol, 2012, 29(3):1586-91.
|
| [16] |
Karn T, Pusztai L, Ruckhäberle E, et al. Melanoma antigen family A identifi ed by the bimodality index defi nes a subset of triple negative breast cancers as candidates for immune response augmentation[J]. Eur J Cancer, 2012, 48(1):12-23.
|
| [17] |
Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes[J]. Pituitary, 20 10,13(1): 29-38.
|
| [18] |
Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells[J]. Clin Cancer Res, 2010,16(13): 34 85-94.
|
| [19] |
Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specifi c approach to therapy[J]. Clin Lung Cancer, 2009, 10(5):371-4.
|
| [20] |
Mkrtichyan M, Ghochikyan A, Davtyan H, et al. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma[J]. Cell Immunol, 2011,270(2): 188-97.
|
下载:
